AGENDA:

I. INTRODUCTION: RELEVANCE FOR MEDICAL DIRECTORS AND LONG-TERM CARE — BARNEY SPIVACK, MD, CMD, FACP

II. HERPES ZOSTER: THE DISEASE AND ITS COMPLICATIONS — MYRON J. LEVIN, MD

III. PREVENTION OF HERPES ZOSTER AND POSTHERPETIC NEURALGIA — MICHAEL N. OXMAN, MD

IV. QUESTIONS AND PANEL DISCUSSION — Identification of Unresolved Issues

BARNEY SPIVACK, MD, CMD, FACP
MICHAEL N. OXMAN, MD
MYRON J. LEVIN, MD

---

Faculty

BARNEY SPIVACK, MD, CMD, FACP
LIFECARE INC.
SHELTON, CT

MICHAEL N. OXMAN, MD
UNIVERSITY OF CALIFORNIA – SAN DIEGO
SAN DIEGO, CA

MYRON J. LEVIN, MD
UNIVERSITY OF COLORADO HEALTH SCIENCES CENTER
DENVER, CO

---

This activity is sponsored by the North American Center for Continuing Medical Education.

---

This activity is supported by an educational grant from Merck & Co.

---

Target Audience:

Physician Medical Directors

---

Learning Objectives:

Upon completion of this educational activity, participants should be able to:
• Discuss the importance of herpes zoster prevention and management, especially among Medical Directors and other practitioners in long-term care
• Describe the pathogenesis and treatment of herpes zoster and of the impact of aging on the expression of herpes zoster
• Utilize special consideration in the treatment of postherpetic neuralgia especially regarding its management and impact in older adults
• Describe the rationale for preventing herpes zoster and of the major findings of the Shingles Prevention Study
• Utilize current expert recommendations regarding the use of zoster vaccine in older adults in the clinical practice setting.

---

Accreditation:

MD/DO: This activity is sponsored by the North American Center for Continuing Medical Education (NACCME). NACCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. NACCME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. This activity has been planned and produced in accordance with the ACCME Essential Areas and Policies

---

Disclosure Policy:

Off-Label/Unapproved Usage Disclosure:
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither NACCME nor Merck & Co. recommends the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosures:
All those with control over the content of continuing education programs sponsored by NACCME are expected to disclose whether they do or do not have any real or apparent conflict(s) of interest or other relationships related to the content of their presentation(s). It is not assumed that these relationships will have an adverse impact on presentations; they are simply noted here to fully inform participants.

Dr. Levin has disclosed that he has received grant/research support and is a consultant, scientific advisor, and member of the speakers’ bureau for Merck & Co.

Dr. Oxman has disclosed that he has received grant/research support from Merck & Co.

Dr. Spivack has disclosed that he is a member of the speakers’ bureau for Novartis.